252 related articles for article (PubMed ID: 28718406)
1. Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy.
Rey S; Schito L; Wouters BG; Eliasof S; Kerbel RS
Trends Cancer; 2017 Jul; 3(7):529-541. PubMed ID: 28718406
[TBL] [Abstract][Full Text] [Related]
2. The Sabotaging Role of Myeloid Cells in Anti-Angiogenic Therapy: Coordination of Angiogenesis and Immune Suppression by Hypoxia.
Li C; Liu T; Bazhin AV; Yang Y
J Cell Physiol; 2017 Sep; 232(9):2312-2322. PubMed ID: 27935039
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer.
Wigerup C; Påhlman S; Bexell D
Pharmacol Ther; 2016 Aug; 164():152-69. PubMed ID: 27139518
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways.
Rohwer N; Cramer T
Drug Resist Updat; 2011 Jun; 14(3):191-201. PubMed ID: 21466972
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis and Metabolism: Entwined for Therapy Resistance.
Jiménez-Valerio G; Casanovas O
Trends Cancer; 2017 Jan; 3(1):10-18. PubMed ID: 28718423
[TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic therapy and tumor progression.
Blagosklonny MV
Cancer Cell; 2004 Jan; 5(1):13-7. PubMed ID: 14749122
[TBL] [Abstract][Full Text] [Related]
7. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia.
Rapisarda A; Melillo G
Nat Rev Clin Oncol; 2012 Apr; 9(7):378-90. PubMed ID: 22525710
[TBL] [Abstract][Full Text] [Related]
8. Targeting tumour angiogenesis with small molecule inhibitors of hypoxia inducible factor.
Nordgren IK; Tavassoli A
Chem Soc Rev; 2011 Aug; 40(8):4307-17. PubMed ID: 21483947
[TBL] [Abstract][Full Text] [Related]
9. Antiangiogenic therapy: a novel approach to overcome tumor hypoxia.
Peng F; Chen M
Chin J Cancer; 2010 Aug; 29(8):715-20. PubMed ID: 20663317
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis.
Mizukami Y; Kohgo Y; Chung DC
Clin Cancer Res; 2007 Oct; 13(19):5670-4. PubMed ID: 17908955
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA inhibits β-catenin/VEGF-mediated angiogenesis by targeting TGF-β1 in normoxic and HIF-1α in hypoxic microenvironments in human colorectal cancer.
Sui H; Zhao J; Zhou L; Wen H; Deng W; Li C; Ji Q; Liu X; Feng Y; Chai N; Zhang Q; Cai J; Li Q
Cancer Lett; 2017 Sep; 403():86-97. PubMed ID: 28602978
[TBL] [Abstract][Full Text] [Related]
12. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads.
Rapisarda A; Shoemaker RH; Melillo G
Cell Cycle; 2009 Dec; 8(24):4040-3. PubMed ID: 19923892
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia: a key regulator of angiogenesis in cancer.
Liao D; Johnson RS
Cancer Metastasis Rev; 2007 Jun; 26(2):281-90. PubMed ID: 17603752
[TBL] [Abstract][Full Text] [Related]
15. The ever-expanding role of HIF in tumour and stromal biology.
LaGory EL; Giaccia AJ
Nat Cell Biol; 2016 Apr; 18(4):356-65. PubMed ID: 27027486
[TBL] [Abstract][Full Text] [Related]
16. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
17. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
18. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2.
Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X
Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350
[TBL] [Abstract][Full Text] [Related]
19. Antiangiogenic Effect of Flavonoids and Chalcones: An Update.
Mirossay L; Varinská L; Mojžiš J
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271940
[TBL] [Abstract][Full Text] [Related]
20. Magnolol suppresses hypoxia-induced angiogenesis via inhibition of HIF-1α/VEGF signaling pathway in human bladder cancer cells.
Chen MC; Lee CF; Huang WH; Chou TC
Biochem Pharmacol; 2013 May; 85(9):1278-87. PubMed ID: 23416116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
